Growth Metrics

Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2016 - 2023)

Historic Non-Current Deferred Tax Liability for Anika Therapeutics (ANIK) over the last 14 years, with Q3 2023 value amounting to $2.0 million.

  • Anika Therapeutics' Non-Current Deferred Tax Liability fell 7125.0% to $2.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.0 million, marking a year-over-year decrease of 7125.0%. This contributed to the annual value of $6.4 million for FY2022, which is 3663.48% down from last year.
  • Latest data reveals that Anika Therapeutics reported Non-Current Deferred Tax Liability of $2.0 million as of Q3 2023, which was down 7125.0% from $3.2 million recorded in Q2 2023.
  • Anika Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $16.0 million during Q1 2020, with a 5-year trough of $2.0 million in Q3 2023.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $8.2 million (2022), whereas its average is $8.4 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 37314.05% in 2020, then crashed by 7125.0% in 2023.
  • Anika Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $4.3 million in 2019, then soared by 174.65% to $11.9 million in 2020, then dropped by 14.61% to $10.2 million in 2021, then plummeted by 36.63% to $6.4 million in 2022, then plummeted by 69.62% to $2.0 million in 2023.
  • Its Non-Current Deferred Tax Liability was $2.0 million in Q3 2023, compared to $3.2 million in Q2 2023 and $4.1 million in Q1 2023.